213 related articles for article (PubMed ID: 31133590)
1. End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study.
Moreno Velásquez I; Tribaldos Causadias M; Valdés R; Gómez B; Motta J; Cuero C; Herrera-Ballesteros V
BMJ Open; 2019 May; 9(5):e027229. PubMed ID: 31133590
[TBL] [Abstract][Full Text] [Related]
2. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
Wong CKH; Chen J; Fung SKS; Mok MMY; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
Nephrol Dial Transplant; 2019 Sep; 34(9):1565-1576. PubMed ID: 30668781
[TBL] [Abstract][Full Text] [Related]
3. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
Zhang H; Zhang C; Zhu S; Ye H; Zhang D
BMC Health Serv Res; 2020 Feb; 20(1):122. PubMed ID: 32059726
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
[TBL] [Abstract][Full Text] [Related]
5. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
Liu FX; Walton SM; Leipold R; Isbell D; Golper TA
Perit Dial Int; 2014; 34(7):749-57. PubMed ID: 25292402
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
7. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
[TBL] [Abstract][Full Text] [Related]
8. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
De Vecchi AF; Dratwa M; Wiedemann ME
Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
[TBL] [Abstract][Full Text] [Related]
9. A cost evaluation of peritoneal dialysis and hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil.
de Abreu MM; Walker DR; Sesso RC; Ferraz MB
Perit Dial Int; 2013; 33(3):304-15. PubMed ID: 23209041
[TBL] [Abstract][Full Text] [Related]
10. Financial implications of dialysis modalities in the developing world: A Chinese perspective.
Liu J; Hutton DW; Gu Y; Hu Y; Li Y; Ma L; Zeng X; Fu P
Perit Dial Int; 2020 Mar; 40(2):193-201. PubMed ID: 32063196
[TBL] [Abstract][Full Text] [Related]
11. Budget Impact Analysis of the Change in Peritoneal Dialysis Use Rate in Korea.
Kim J; Lee NR; Son SK; Lee JP; Park JT; Kim YJ; Ryu DR
Perit Dial Int; 2019; 39(6):547-552. PubMed ID: 31337696
[No Abstract] [Full Text] [Related]
12. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of renal replacement therapies in Finland.
Salonen T; Reina T; Oksa H; Sintonen H; Pasternack A
Am J Kidney Dis; 2003 Dec; 42(6):1228-38. PubMed ID: 14655195
[TBL] [Abstract][Full Text] [Related]
14. Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan.
Tang CH; Chen HH; Wu MJ; Hsu BG; Tsai JC; Kuo CC; Lin SP; Chen TH; Sue YM
BMJ Open; 2019 Mar; 9(3):e023062. PubMed ID: 30904836
[TBL] [Abstract][Full Text] [Related]
15. The financial implications for Medicare of greater use of peritoneal dialysis.
Neil N; Guest S; Wong L; Inglese G; Bhattacharyya SK; Gehr T; Walker DR; Golper T
Clin Ther; 2009 Apr; 31(4):880-8. PubMed ID: 19446160
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in end stage renal disease: a multicentre comparative study.
Gayle F; Soyibo AK; Gilbert DT; Manzanares J; Barton EN
West Indian Med J; 2009 Jun; 58(3):235-42. PubMed ID: 20043531
[TBL] [Abstract][Full Text] [Related]
17. Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System.
Goncalves GMR; Silva END
PLoS One; 2018; 13(10):e0203992. PubMed ID: 30273345
[TBL] [Abstract][Full Text] [Related]
18. Health care costs of peritoneal dialysis technique failure and dialysis modality switching.
Chui BK; Manns B; Pannu N; Dong J; Wiebe N; Jindal K; Klarenbach SW
Am J Kidney Dis; 2013 Jan; 61(1):104-11. PubMed ID: 22901772
[TBL] [Abstract][Full Text] [Related]
19. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
[TBL] [Abstract][Full Text] [Related]
20. The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis.
Liu FX; Treharne C; Culleton B; Crowe L; Arici M
BMC Nephrol; 2014 Oct; 15():161. PubMed ID: 25278356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
